Alliancebernstein L.P. Sells 5,500 Shares of Chimerix, Inc. (NASDAQ:CMRX)
Alliancebernstein L.P. cut its position in Chimerix, Inc. (NASDAQ:CMRX) by 7.8% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 64,800 shares of the biopharmaceutical company’s stock after selling 5,500 shares during the period. Alliancebernstein L.P.’s holdings in Chimerix were worth $413,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently made changes to their positions in CMRX. American International Group Inc. boosted its stake in Chimerix by 7.1% in the first quarter. American International Group Inc. now owns 26,281 shares of the biopharmaceutical company’s stock worth $168,000 after buying an additional 1,733 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in Chimerix during the first quarter worth approximately $776,000. Trexquant Investment LP acquired a new stake in Chimerix during the first quarter worth approximately $226,000. Parametric Portfolio Associates LLC boosted its stake in Chimerix by 11.0% in the first quarter. Parametric Portfolio Associates LLC now owns 282,948 shares of the biopharmaceutical company’s stock worth $1,805,000 after buying an additional 28,003 shares in the last quarter. Finally, TFS Capital LLC acquired a new stake in Chimerix during the first quarter worth approximately $684,000. 65.63% of the stock is currently owned by institutional investors.
Shares of Chimerix, Inc. (NASDAQ CMRX) traded up 1.35% during midday trading on Friday, hitting $4.52. The stock had a trading volume of 8,785 shares. The stock’s market cap is $212.65 million. Chimerix, Inc. has a 52-week low of $3.66 and a 52-week high of $6.64. The firm has a 50 day moving average price of $5.14 and a 200-day moving average price of $5.44.
Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.05. Chimerix had a negative net margin of 1,514.27% and a negative return on equity of 24.68%. The firm had revenue of $0.68 million during the quarter, compared to the consensus estimate of $1.28 million. Equities analysts predict that Chimerix, Inc. will post ($1.68) EPS for the current fiscal year.
CMRX has been the topic of a number of recent analyst reports. FBR & Co reissued a “hold” rating and set a $7.00 price target on shares of Chimerix in a report on Monday, May 1st. Zacks Investment Research cut Chimerix from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Cowen and Company reissued a “hold” rating and set a $6.00 price target on shares of Chimerix in a report on Friday, April 28th. Finally, ValuEngine cut Chimerix from a “hold” rating to a “sell” rating in a report on Friday. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $7.56.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Want to see what other hedge funds are holding CMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chimerix, Inc. (NASDAQ:CMRX).
Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.